Merrion Pharma files for $146M IPO

Merrion Pharmaceuticals has filed for an IPO to raise up to $146 million. The company has been developing technology that increases the bioavailability of drugs in the GI tract. Its researchers have been working to develop oral drugs that replace injectables.

- see this press release
- here's the report on the IPO from TechJournal

ALSO: Amicus Therapeutics, which is working on new therapies for genetic diseases, has registered an IPO that is designed to raise $86.25 million. Amicus has raised about $146 million in venture funds, with backers that include New Enterprise Associates, Frazier Healthcare Ventures, Prospect Venture Partners, CHL Medical Partners, Canaan Partners, Quaker BioVenture. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.